JPWO2023049694A5 - - Google Patents
Info
- Publication number
- JPWO2023049694A5 JPWO2023049694A5 JP2024518659A JP2024518659A JPWO2023049694A5 JP WO2023049694 A5 JPWO2023049694 A5 JP WO2023049694A5 JP 2024518659 A JP2024518659 A JP 2024518659A JP 2024518659 A JP2024518659 A JP 2024518659A JP WO2023049694 A5 JPWO2023049694 A5 JP WO2023049694A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- subject
- binding fragment
- doses
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163247637P | 2021-09-23 | 2021-09-23 | |
| US63/247,637 | 2021-09-23 | ||
| PCT/US2022/076694 WO2023049694A1 (en) | 2021-09-23 | 2022-09-20 | Methods of treating multiple myeloma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024534602A JP2024534602A (ja) | 2024-09-20 |
| JP2024534602A5 JP2024534602A5 (https=) | 2025-09-22 |
| JPWO2023049694A5 true JPWO2023049694A5 (https=) | 2025-09-22 |
Family
ID=83996580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024518659A Pending JP2024534602A (ja) | 2021-09-23 | 2022-09-20 | 多発性骨髄腫を処置する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240343819A1 (https=) |
| EP (1) | EP4405393A1 (https=) |
| JP (1) | JP2024534602A (https=) |
| CA (1) | CA3232799A1 (https=) |
| TW (1) | TW202327650A (https=) |
| WO (1) | WO2023049694A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12138246B2 (en) | 2022-05-20 | 2024-11-12 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| US11951096B2 (en) | 2022-05-20 | 2024-04-09 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| IL316750A (en) | 2022-05-20 | 2025-01-01 | Springworks Therapeutics Inc | Treatments with Nirogesstat |
| US12036207B2 (en) | 2022-05-20 | 2024-07-16 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| WO2025117764A1 (en) * | 2023-12-01 | 2025-06-05 | Teneoone, Inc. | Methods for the treatment of multiple myeloma |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| WO2000046750A1 (en) | 1999-02-05 | 2000-08-10 | Samsung Electronics Co., Ltd. | Image texture retrieving method and apparatus thereof |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| BRPI0513959A (pt) | 2004-07-30 | 2008-05-20 | Rinat Neuroscience Corp | anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| WO2008070593A2 (en) | 2006-12-01 | 2008-06-12 | Seattle Genetics, Inc. | Variant target binding agents and uses thereof |
| US8163551B2 (en) | 2008-05-02 | 2012-04-24 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
| NZ603698A (en) | 2008-07-08 | 2014-03-28 | Abbvie Inc | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
| KR20120060877A (ko) | 2009-09-01 | 2012-06-12 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| AU2010306677B2 (en) | 2009-10-15 | 2013-05-23 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| US8735546B2 (en) | 2010-08-03 | 2014-05-27 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| US20170233484A1 (en) | 2016-02-17 | 2017-08-17 | Seattle Genetics, Inc. | Bcma antibodies and use of same to treat cancer and immunological disorders |
| BR112021020409A2 (pt) * | 2019-04-10 | 2021-12-07 | Glaxosmithkline Ip Dev Ltd | Terapia de combinação com anticorpo anti-bcma e inibidor de gama-secretase |
-
2022
- 2022-09-19 TW TW111135302A patent/TW202327650A/zh unknown
- 2022-09-20 CA CA3232799A patent/CA3232799A1/en active Pending
- 2022-09-20 WO PCT/US2022/076694 patent/WO2023049694A1/en not_active Ceased
- 2022-09-20 US US18/694,483 patent/US20240343819A1/en active Pending
- 2022-09-20 EP EP22797206.4A patent/EP4405393A1/en active Pending
- 2022-09-20 JP JP2024518659A patent/JP2024534602A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7579227B2 (ja) | 瘻孔を伴うクローン病の治療用ベドリズマブ | |
| JP7160533B2 (ja) | 多発性骨髄腫（ｍｍ）の処置 | |
| JP2011506483A5 (https=) | ||
| WO2018223923A1 (zh) | Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| AU2025203436A1 (en) | Treatment paradigm for an anti-CD19 antibody and venetoclax combination treatment | |
| US20250075007A1 (en) | Treatment of Al Amyloidosis with the Combination of Monoclonal Antibodies Agains Immunoglobulin Light Chains and the CD38 Cell Membrane Molecule on Antibody-Producing And Other Immune Cells | |
| JPWO2023049694A5 (https=) | ||
| JPWO2021113701A5 (https=) | ||
| JPWO2022076462A5 (https=) | ||
| JPWO2021224499A5 (https=) | ||
| JP2024525870A (ja) | 抗ｐｌａ２ｒ自己抗体媒介膜性腎症の治療 | |
| JPWO2022053655A5 (https=) | ||
| JPWO2021195362A5 (https=) | ||
| JPWO2019152743A5 (https=) | ||
| IL314344A (en) | Bispecific antibodies against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma | |
| JPWO2023133388A5 (https=) | ||
| RU2025131684A (ru) | Способы лечения множественной миеломы | |
| JP2020517648A5 (https=) | ||
| JPWO2022060955A5 (https=) | ||
| JPWO2022099257A5 (https=) | ||
| JPWO2020176748A5 (https=) | ||
| JPWO2023177772A5 (https=) | ||
| JPWO2022090158A5 (https=) | ||
| RU2025101350A (ru) | Дозирование для лечения биспецифическими антителами к fcrh5/cd3 | |
| RU2023130537A (ru) | Введение доз для лечения биспецифическим антителом к cd20/cd3 |